874518-45-3

Upstream product

• 64-17-5 ethanol 
• 1145-15-9 5-(3,4-dimethoxyphenyl)pentanoic acid 
• 101619-71-0 (2E,4E)-ethyl 5-(3,4-dimethoxyphenyl)penta-2,4-dienoate 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 20583-78-2 3,4-dimethoxy-cinnamic acid ethyl ester 
• 5462-13-5 ethyl 3-(3,4-dimethoxyphenyl)propionate 
• 61871-67-8 3-(3,4-Dimethoxyphenyl)propanal 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 27798-73-8 methyl 3-(3,4-dimethoxyphenyl)propionate 
• 2107-70-2 3,4-methoxycinnamic acid 
• 14737-89-4 3,4-dimethoxy-trans-cinnamic acid 
• 4378-55-6 5-(3,4-dimethoxy-phenyl)-5-oxo-pentanoic acid 
• 91-16-7 1,2-dimethoxybenzene 
• 108-55-4 glutaric anhydride, 

Downstream Products

• 220396-70-3 2-(4-ethoxycarbonylbutyl)-4,5-dimethoxybenzenesulfonyl chloride 
• 220396-75-8 2-(4-carboxybutyl)-4,5-dimethoxybenzenesulfonamide 
• 220396-72-5 2-(4-ethoxycarbonylbutyl)-4,5-dimethoxybenzenesulfonamide 
• 1145-15-9 5-(3,4-dimethoxyphenyl)pentanoic acid 
• 1452406-10-8 6-(3,4-dimethoxyphenyl)-1,1,1-trifluorohexan-2-one 
• 1452406-19-7 7-(3,4-dimethoxyphenyl)-1,1,1,2,2-pentafluoroheptan-3-one 
• 91869-09-9 5-(3,4-dimethoxyphenyl)pentanoyl chloride 
• 79623-17-9 1,2-dimethoxy-4-(5-hydroxypentyl)benzene 
• 152867-95-3 5-(3,4-dimethoxyphenyl)pentan-1-al 

Relevant academic research and scientific papers

In silico design and synthesis of N-arylalkanyl 2-naphthamides as a new class of non-purine xanthine oxidase inhibitors

A series of N-arylalkanyl 2-naphthamides (Xa~e), which were predicted from virtual molecular docking on a built xanthine oxidase template as potential inhibitors, were synthesized. Their inhibitory activity against xanthine oxidase was assayed. Among these prepared, compounds Xb (IC50 13.6?μM), Xc (IC50 13.1?μM), and Xd (IC50 12.5?μM) showed comparable inhibitory activity to allopurinol (IC50 22.1?μM). The in vitro assay result correlated well with molecular docking scores, ΔG?=??16.99, ?17.66, and ?17.13 Kcal/mol, respectively. On the potassium oxonate-induced hyperuricemic mice model, oral administration of Xc-Ac (40 mg/ Kg), the per-O-acetylated Xc, could reduce the blood uric acid level by 60% in comparison to the normal control group and is statistically significant (p .01) while compared with the hyperuricemic mice group.

Synthesis, in vitro and in silico evaluation of diaryl heptanones as potential 5LOX enzyme inhibitors

A new series of diaryl heptanones (12a-q) were synthesized and their structures were confirmed by its 1H, 13C NMR and Mass spectral data. These analogs were evaluated for their anti-oxidant activity and potential to inhibit 5-lipoxygenase. Compounds 12k and 12o showed potent in vitro 5-lipoxygenase enzyme inhibitory activity with IC50 values of 22.2, 21.5 μM, which are comparable to curcumin (24.4 μM). Further they also have shown significant antioxidant activity. Molecular docking studies clearly showed correlation between binding energy and potency of these compounds.

New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2

Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as an important pharmaceutical target. Selective and potent GVIA iPLA2 inhibitors can be used to study its role in various neurological diso

Ring enlargement of eight- and nine-membered cyclic sulfonamide derivatives in reactions with 3-amino-2H-azirines

The reactions of 3-dimethylamino-2H-azirines (1) with 3,4,5,6- tetrahydro-8,9-dimethoxy-2H-1,2-benzothiazocin-3-one 1,1-dioxide (6a) in acetonitrile gave the correspondingly substituted 3-dimethylamino- 4,5,6,7,8,9-hexahydrobenzo-1-thia-2,5-diazacyclounde